USC Keck School of Medicine, Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3440, Los Angeles, CA, 90033, USA.
Prostate cancer is among the more common and less lethal malignancies, yielding a large population of survivors. The incidence of hypogonadism increases in the same elderly population of men who most frequently develop prostate cancer, and the risk of becoming hypogonadal is increased further by prostate cancer therapy. The relative safety of replacing testosterone to reduce symptoms of hypogonadism in men who have been treated for prostate cancer is not well established. We review the available data, provide suggestions for approaching the management of prostate cancer survivors who suffer hypogonadal symptoms, and describe other diagnostic and therapeutic uses of testosterone that have been employed in patients with prostate cancer.
Written by:
Dorff TB, Vogelzang NJ.
Are you the author?
Reference: Curr Urol Rep. 2011 Mar 2. Epub ahead of print.
doi: 10.1007/s11934-011-0176-2
PubMed Abstract
PMID: 21365235
UroToday.com Prostate Cancer Section